> It seems to indicate that mRNA-1273 vaccination antibodies work better against spike mutation. Yes [4] does kind of say that - but it does not claim that thi

> It seems to indicate that mRNA-1273 vaccination antibodies work better against spike mutation. Yes [4] does kind of say that - but it does not claim that this provides better protection or benefits individual health outcomes. Here are a few key nuances and limitations: > We found that the specificity of the mRNA-1273 vaccine-induced RBD-binding antibody response often narrows over time. In contrast, the infection-elicited RBD-binding antibody response often broadens over time. > Additionally, the overall antibody response is more homogeneous for vaccinated than convalescent individuals. > another recent study suggests that mRNA vaccination elicits a different distribution of isotypes and fewer antibodies that cross-react to common-cold coronaviruses as compared to infection > we did not examine effects of mutations or deletions to the N-terminal domain of the spike protein, which can also affect neutralization by vaccine sera. > Our experiments assayed binding of antibodies to isolated RBD expressed by yeast, and so cannot capture mutational effects on trimer conformation or antibodies with quaternary epitopes These nuances have implications for viral evolution, and are particularly important in the context of discussions around compulsory mass vaccination and vaccine resistance.